Drug reduces death from sepsisBMJ 2001; 322 doi: https://doi.org/10.1136/bmj.322.7287.638/b (Published 17 March 2001) Cite this as: BMJ 2001;322:638
- Xavier Bosch
Several drugs given as adjuvant therapy to reduce mortality in patients with sepsis have proved unsuccessful so far. Now a large clinical trial has found that administration of recombinant human activated protein C—or drotrecogin alfa activated—leads to a significant reduction in mortality among patients with severe sepsis.
“Our results indicate that in this population, one additional life would be saved for every 16 patients treated with drotrecogin alfa activated” wrote Gordon Bernard, Vanderbilt University School of Medicine, Nashville, and colleagues (New England Journal of Medicine 2001;344:699-709).
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial